Search results
Showing 916 to 930 of 2184 results for guidelines
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
An approximate guide to the timings for the development of a piece of HealthTech guidance.
Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
applicable) Why this is important:- The evidence review for the NICE guideline on hearing loss found a lack of evidence to establish the...
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.
View recommendations for HTG549Show all sections
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.
Low dose rate brachytherapy for localised prostate cancer (HTG81)
Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.
View recommendations for HTG81Show all sections
Sections for HTG81